TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07650357: A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

Sponsor: Clasp Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 140 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07650357 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07650357 Rescue Dossier →